

## Endocrinología, Diabetes y Nutrición



## 5 - IMPLICATION OF MIR200A, MIR103 AND MIR383 IN THE SILENCING OF CORTICOTROPH TUMORS

A.  $García-Martínez^a$ , B.  $López-Mu\~noz^a$ , S.  $Martínez-López^a$ , C.  $Fajardo^b$ , R.  $C\'amara^c$ , C.  $Lamas^d$ , M.E.  $Torregrosa-Quesada^a$ , I.  $Aranda^a$  and A.  $Pic\'o^{a,e}$ 

<sup>a</sup>Hospital General Universitario de Alicante-ISABIAL. Alicante. <sup>b</sup>Hospital La Ribera. Alzira. <sup>c</sup>Hospital Universitario y Politécnico La Fe. Valencia. <sup>d</sup>Complejo Hospitalario Universitario de Albacete. <sup>e</sup>Universidad Miguel Hernández. Alicante.

## Resumen

**Introduction:** Silencing mechanisms of corticotroph tumors (CT) remain unclear. Epigenetic mechanisms can occur during tumorigenesis. MiRNAs capable of inhibiting the expression of *POMC* have been described at the level of neurons of the hypothalamus, which gives us a basis to advance in the knowledge of CT.

**Objectives:** To determine if post-transcriptional regulation by miRNAs is involved in the silencing of CT.

**Methods:** We quantified the relative gene expression of 8 factors (*PKA, MAP3K8, MEK, MAPK3, NGFIB, NURR1, PITX1, STAT3*) and 5 miRNAs (miR375, miR383, miR488, miR200a, miR103) by qRT-PCR with TaqMan probes in 24 functioning CT (fCT) and 23 silent CT (sCT).

**Results:** miR200a and miR103 expression was higher in silent CT than in macro functioning CT (p = 0.049 and p = 0.05, respectively). Both miRNA biomarkers could be a good tool to distinguish between both variants (AUC = 0.739, 95%CI = 0.592-0.887, p = 0.007; AUC = 0.727, 95%CI = 0.574-0.880, p = 0.011, respectively). These two miRNAs correlated negatively with *MAP3K8* (rho = -0.686, p = 0.001 and rho = -0.782, p < 0.001, respectively). MiR383 was up-regulated in functioning ( $3.607 \pm 5.016$ ) and silent ( $8.918 \pm 12.009$ ) CT compared with normal pituitary gland. Using different computational algorithms, we found that *NEUROD1* was a potential target for miR383. Interestingly we observed a negative correlation between *TBX19* and miR383 in both subtypes, stronger in silent CT (rho = -0.583, p = 0.007) than in functioning ones (rho = -0.431, p = 0.051). We also found other interesting potential targets for miR383, as *SSTR2*, *SSTR3* and *SSTR5*. Finally, we observed a negative correlation between miR383 and the expression of *STAT3* (rho = -0.544, p = 0.016) in silent CT.

**Conclusions:** MiR200a and miR103 may be involved in the silencing of this subtype and could be used as diagnostic tool. The negative correlation between miR383 and *TBX19* expression could indicate a potential silencing mechanism of these tumors. Moreover, miR383 may be a possible therapeutic target in CT.